Cordatus Wealth Management LLC bought a new position in Regeneron Pharmaceuticals Inc (NASDAQ:REGN) in the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 10,350 shares of the biopharmaceutical company’s stock, valued at approximately $4,250,000. Regeneron Pharmaceuticals makes up about 2.3% of Cordatus Wealth Management LLC’s portfolio, making the stock its 7th largest holding.
A number of other hedge funds have also bought and sold shares of the business. BlackRock Inc. grew its position in Regeneron Pharmaceuticals by 1.1% in the fourth quarter. BlackRock Inc. now owns 5,929,225 shares of the biopharmaceutical company’s stock worth $2,214,564,000 after acquiring an additional 67,241 shares in the last quarter. Vanguard Group Inc grew its position in Regeneron Pharmaceuticals by 1.3% in the third quarter. Vanguard Group Inc now owns 5,754,927 shares of the biopharmaceutical company’s stock worth $2,325,220,000 after acquiring an additional 75,868 shares in the last quarter. FMR LLC lifted its stake in shares of Regeneron Pharmaceuticals by 6.6% in the fourth quarter. FMR LLC now owns 5,347,376 shares of the biopharmaceutical company’s stock worth $1,997,245,000 after buying an additional 330,875 shares during the last quarter. Geode Capital Management LLC lifted its stake in shares of Regeneron Pharmaceuticals by 7.8% in the fourth quarter. Geode Capital Management LLC now owns 1,078,453 shares of the biopharmaceutical company’s stock worth $402,138,000 after buying an additional 78,143 shares during the last quarter. Finally, American Century Companies Inc. lifted its stake in shares of Regeneron Pharmaceuticals by 16.6% in the fourth quarter. American Century Companies Inc. now owns 1,003,471 shares of the biopharmaceutical company’s stock worth $374,796,000 after buying an additional 142,779 shares during the last quarter. 67.63% of the stock is owned by institutional investors.
REGN has been the subject of a number of analyst reports. Cantor Fitzgerald restated a “hold” rating and issued a $441.00 price objective on shares of Regeneron Pharmaceuticals in a research note on Wednesday, February 6th. BidaskClub cut shares of Regeneron Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research note on Thursday, April 25th. Oppenheimer boosted their price objective on shares of Regeneron Pharmaceuticals from $440.00 to $480.00 and gave the stock an “outperform” rating in a research note on Thursday, February 7th. Jefferies Financial Group reduced their price objective on shares of Regeneron Pharmaceuticals from $376.00 to $343.00 and set a “hold” rating for the company in a research note on Wednesday, April 17th. Finally, Canaccord Genuity restated a “hold” rating and issued a $353.00 price objective (down from $408.00) on shares of Regeneron Pharmaceuticals in a research note on Wednesday, May 8th. Three analysts have rated the stock with a sell rating, eleven have assigned a hold rating, five have given a buy rating and one has issued a strong buy rating to the company’s stock. Regeneron Pharmaceuticals presently has an average rating of “Hold” and a consensus target price of $404.88.
In related news, EVP Neil Stahl sold 9,853 shares of the company’s stock in a transaction on Tuesday, May 14th. The shares were sold at an average price of $305.74, for a total transaction of $3,012,456.22. Following the completion of the transaction, the executive vice president now directly owns 47,450 shares in the company, valued at approximately $14,507,363. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, major shareholder Sanofi sold 131,115 shares of the company’s stock in a transaction on Friday, March 8th. The shares were sold at an average price of $412.17, for a total transaction of $54,041,669.55. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 141,968 shares of company stock valued at $57,360,056. Corporate insiders own 11.84% of the company’s stock.
NASDAQ:REGN opened at $304.62 on Thursday. The firm has a market cap of $33.35 billion, a P/E ratio of 15.38, a P/E/G ratio of 1.44 and a beta of 1.08. Regeneron Pharmaceuticals Inc has a one year low of $291.10 and a one year high of $442.00. The company has a quick ratio of 3.78, a current ratio of 4.58 and a debt-to-equity ratio of 0.08.
Regeneron Pharmaceuticals (NASDAQ:REGN) last released its earnings results on Tuesday, May 7th. The biopharmaceutical company reported $4.45 EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $5.24 by ($0.79). The company had revenue of $1.71 billion for the quarter, compared to analyst estimates of $1.76 billion. Regeneron Pharmaceuticals had a net margin of 35.13% and a return on equity of 26.95%. Regeneron Pharmaceuticals’s revenue for the quarter was up 13.3% compared to the same quarter last year. During the same quarter in the previous year, the company earned $4.67 earnings per share. As a group, analysts forecast that Regeneron Pharmaceuticals Inc will post 18.37 earnings per share for the current fiscal year.
Regeneron Pharmaceuticals Company Profile
Regeneron Pharmaceuticals, Inc, a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for treating various medical conditions worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema (DME); myopic choroidal neovascularization; and diabetic retinopathy in patients with DME, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion.
See Also: Investing strategies using the yield curve
Want to see what other hedge funds are holding REGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regeneron Pharmaceuticals Inc (NASDAQ:REGN).